Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Huntington Disease Pipeline Drugs Market Overview

Huntington’s disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

The Huntington Disease pipeline drugs market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report also provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Huntington Disease Pipeline Drugs Market Segmentation by Targets

The key targets in the Huntington Disease pipeline drugs market are Huntingtin, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor NMDA Type Subunit, Nuclear Factor Erythroid 2 Related Factor 2, Synaptic Vesicular Amine Transporter, Alpha 1 Adrenergic Receptor, Beta 1 Adrenergic Receptor, C5a Anaphylatoxin Chemotactic Receptor 1, and Caspase 6, among others. Huntingtin is the leading target in the pipeline products market.

Huntington Disease Pipeline Drugs Market Analysis by Targets

Huntington Disease Pipeline Products Market Analysis by Targets

For more target insights into the Huntington Disease pipeline drugs market, download a free report sample

Huntington Disease Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Huntington Disease pipeline products market are Huntingtin Inhibitor, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Synaptic Vesicular Amine Transporter Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Caspase 6 Inhibitor, and D2 Dopamine Receptor Antagonist, among others. Huntingtin Inhibitor is the leading mechanism of action in the pipeline.

Huntington Disease Pipeline Products Market Analysis by Mechanisms of Action

Huntington Disease Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Huntington Disease pipeline products market, download a free report sample

Huntington Disease Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Huntington Disease pipeline drugs market are oral, intravenous, intrathecal, subcutaneous, buccal, intracerebral, parenteral, intramuscular, ophthalmic, and topical. Most of the pipeline products are administered through the oral route.

Huntington Disease Pipeline Drugs Market Analysis by Routes of Administration

Huntington Disease Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Huntington Disease pipeline drugs market, download a free report sample

Huntington Disease Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Huntington Disease pipeline products market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, synthetic peptide, monoclonal antibody, oligonucleotide, peptide, antisense RNAi oligonucleotide, and biologic, among others. Small molecule is the leading molecule type in the market.

Huntington Disease Pipeline Products Market Analysis by Molecule Types

Huntington Disease Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Huntington Disease pipeline products market, download a free report sample

Huntington Disease Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Huntington Disease pipeline products market are Medesis Pharma SA, AFFiRiS AG, Anima Biotech Inc, Luye Pharma Group Ltd, MMJ International Holdings Corp, Origami Therapeutics Inc, Prous Institute for Biomedical Research SA, Retrotope Inc, SOLA Biosciences LLC, and SOM Biotech SL. Medesis Pharma SA is the leading company in the pipeline products market.

Huntington Disease Pipeline Products Market Analysis by Companies

Huntington Disease Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the Huntington Disease pipeline products market, download a free report sample

Huntington Disease pipeline Products Market Report Overview

Key Targets Huntingtin, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor NMDA Type Subunit, Nuclear Factor Erythroid 2 Related Factor 2, Synaptic Vesicular Amine Transporter, Alpha 1 Adrenergic Receptor, Beta 1 Adrenergic Receptor, C5a Anaphylatoxin Chemotactic Receptor 1, and Caspase 6
Key Mechanisms of Action Huntingtin Inhibitor, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Synaptic Vesicular Amine Transporter Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Caspase 6 Inhibitor, and D2 Dopamine Receptor Antagonist
Key Routes of Administration Oral, Intravenous, Intrathecal, Subcutaneous, Buccal, Intracerebral, Parenteral, Intramuscular, Ophthalmic, and Topical
Key Molecule Type Small Molecule, Gene Therapy, Antisense Oligonucleotide, Cell Therapy, Synthetic Peptide, Monoclonal Antibody, Oligonucleotide, Peptide, Antisense RNAi Oligonucleotide, and Biologic
Leading Companies Medesis Pharma SA, AFFiRiS AG, Anima Biotech Inc, Luye Pharma Group Ltd, MMJ International Holdings Corp, Origami Therapeutics Inc, Prous Institute for Biomedical Research SA, Retrotope Inc, SOLA Biosciences LLC, and SOM Biotech SL

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System).

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

FAQs

  • The key targets in the Huntington Disease pipeline products market are Huntingtin, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor NMDA Type Subunit, Nuclear Factor Erythroid 2 Related Factor 2, Synaptic Vesicular Amine Transporter, Alpha 1 Adrenergic Receptor, Beta 1 Adrenergic Receptor, C5a Anaphylatoxin Chemotactic Receptor 1, and Caspase 6, among others.

  • The key mechanisms of action in the Huntington Disease pipeline products market are Huntingtin Inhibitor, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Synaptic Vesicular Amine Transporter Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Caspase 6 Inhibitor, and D2 Dopamine Receptor Antagonist, among others.

  • The key routes of administration in the Huntington Disease pipeline products market are oral, intravenous, intrathecal, subcutaneous, buccal, intracerebral, parenteral, intramuscular, ophthalmic, and topical.

  • The key molecule types in the Huntington Disease pipeline products market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, synthetic peptide, monoclonal antibody, oligonucleotide, peptide, antisense RNAi oligonucleotide, and biologic, among others.

  • Some of the leading companies in the Huntington Disease pipeline products market are Medesis Pharma SA, AFFiRiS AG, Anima Biotech Inc, Luye Pharma Group Ltd, MMJ International Holdings Corp, Origami Therapeutics Inc, Prous Institute for Biomedical Research SA, Retrotope Inc, SOLA Biosciences LLC, and SOM Biotech SL.

What our clients have to say

More Reports

View More Reports